GEO DataSets

(Submitter supplied) Imatinib, as the first-line agent of chronic myeloid leukemia (CML), is ineffective in eradicating CML stem/progenitor cells, thus unable to prevent late relapse. Here we present data indicating that fenretinide preferentially targets CD34+ CML cells and enhances the efficacy of imatinib in CML. As tested by colony forming cell assays, both number and size of total colonies derived from CD34+ CML cells were significantly reduced by fenretinide, and by combining fenretinide with imatinib. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

8 Samples

Download data: CEL

(Submitter supplied) We show the molecular and functional characterization of a novel population of lineage-negative CD34-negative (Lin- CD34-) hematopoietic stem cells (HSCs) from chronic myelogenous leukemia (CML) patients at diagnosis. Molecular caryotyping and quantitative analysis of BCR/ABL transcript demonstrated that about one third of CD34- was leukemic. CML CD34- cells showed kinetic quiescence and limited clonogenic capacity. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL8300

6 Samples

Download data: CEL, CHP

(Submitter supplied) Transcriptional profiling of human acute myelogenous leukemia (AML) CD34+ cells treated with 5 μM fenretinide. Two timepoints included are 6h, 12h, covering the apoptosis-induction time window of AML CD34+ cells responsing to the fenretinide treatment. We studied gene expression series in human AML CD34+ cells with or without 5 μM fenretinide treatment by cDNA microarray analysis. Several signal transduction pathways are involve, including stress response, NF-kappaB inhibition and p53 inhibition (p<0.05). more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

6 Samples

Download data: CEL

(Submitter supplied) ABL1 kinase inhibitors such as imatinib mesylate (IM) are effective in managing chronic myelogenous leukemia (CML) but incapable of eliminating leukemia stem cells (LSCs), suggesting that kinase−independent pathways support LSC survival. Given that the bone marrow hypoxic microenvironment supports hematopoietic stem cells, we investigated if hypoxia similarly contributes to LSC persistence. Importantly, we found that while BCR−ABL1 kinase remained effectively inhibited by IM under hypoxia, apoptosis became partially suppressed. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL10558

24 Samples

Download data: TXT

(Submitter supplied) We investigated the ability of HDAC inhibitors (HDACi) to target CML stem cells. Treatment with HDACi combined with IM effectively induced apoptosis in quiescent CML progenitors resistant to elimination by IM alone, and eliminated CML stem cells capable of engrafting immunodeficient mice. In vivo administration of HDACi with IM markedly diminished LSC in a transgenic mouse model of CML. The interaction of IM and HDACi inhibited genes regulating hematopoietic stem cell maintenance and survival. more...

Organism:

Homo sapiens

Type:

Expression profiling by array

Dataset:

GDS4047

Platform:

GPL570

12 Samples

Download data: CEL

Analysis of sorted chronic myelogenous leukemia (CML) CD34+CD38- cells cultured with histone deacetylase inhibitor analog LBH589 (LBH) and/or BCR-ABL tyrosine kinase inhibitor imatinib mesylate (IM). Results provide insight into molecular mechanisms underlying treatment of CML with LBH and IM.

Organism:

Homo sapiens

Type:

Expression profiling by array, transformed count, 4 agent sets

Platform:

GPL570

Series:

GSE20876

12 Samples

Download data: CEL

(Submitter supplied) In our previous study, the roles of zinc finger protein X-linked (ZFX) in CML cells were revealed. We showed that ZFX expression was significantly higher in CML CD34+ cells than in control cells. Overexpression and gene silencing experiments indicated that ZFX promoted the in vitro growth of CML cells, conferred imatinib mesylate (IM) resistance to these cells, and enhanced BCR/ABL-induced malignant transformation. more...

Organism:

Homo sapiens

Type:

Non-coding RNA profiling by array; Expression profiling by array

Platform:

GPL21047

6 Samples

Download data: TXT

(Submitter supplied) GAS2DN could suppress the growth of chronic myeloid leukemia cells, including K562, MEG-01 and CD34+ cells from patients. In addition, GAS2DN inhibited the tumorigenic ability of MEG-01 cells in nude mice. To understand the molecular insight of this inhibitory effect of GAS2DN, global gene expression were performed. The control and GAS2DN-transduced MEG-01 cells were used for microarray analysis.

Organism:

Homo sapiens

Type:

Expression profiling by array

Platform:

GPL570

2 Samples

Download data: CEL

(Submitter supplied) We tested the effect of arginine depleting enzyme BCT-100 (24 hours) on primary normal and CML cells (100ng/mL for primary) as well as the wildtype or ASS1 knock-out K562 cell lines (1000ng/mL for cell lines) Cells were cultured in Plasmax Primary groups were Normal, Normal+bct, CML, CML+BCT Cell line groups were WT, WT+bct, ASS1KO, ASS1KO+BCT

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL18573

52 Samples

Download data: TXT

(Submitter supplied) The goals of this study are to test whether the differences in clinical presentation of pediatric CML are due to unique molecular characteristics that differ from adult CML. Methods: CD34+ hematopoietic stem/progenitor cells mRNA profiles of pediatric normal/CML and adult normal/CML were generated by deep sequencing as reverse paired-end (75 bp) runs on the HiSeq 4000 sequencer. Raw fastq files were trimmed with Trimmomatic/0.36 and reads were aligned to the mm10 reference genome with STAR/2.5.1b aligner. more...

Organism:

Homo sapiens

Type:

Expression profiling by high throughput sequencing

Platform:

GPL20301

39 Samples

Download data: XLSX